REG - Destiny Pharma PLC - To present data at ECCMID Congress

Destiny PharmaAnnouncement

31/03/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220331:nRSe6655Ga&default-theme=true

RNS Number : 6655G  Destiny Pharma PLC  31 March 2022

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Data on the antimicrobial activity of XF-73 against bacteria within biofilms
to be presented at prestigious 2022 ECCMID Congress

 

Brighton, United Kingdom - 31 March 2022 - Destiny Pharma plc (AIM:DEST), a
clinical stage biotechnology company focused on the development of novel
medicines to prevent life threatening infections, today announces that an
abstract providing data on the antimicrobial activity of XF-73 against
bacteria within biofilms has been accepted for presentation at Europe's
premier antimicrobials congress, the 32 (https://www.eccmid.org/) (nd
(https://www.eccmid.org/) ) European Congress of Clinical Microbiology &
Infectious Diseases (https://www.eccmid.org/) (ECCMID), to be held 23- 26
April, 2022.  The data were generated as part of a research collaboration
with Aston University.

 

Presentation Title: Antibacterial efficacy of XF-73 via two mechanisms of
action against Gram-positive microorganisms in biofilm mode of growth

 

Presenting Author: Isabella Romeo-Melody

 

Abstract #: 04656

 

Session: Preclinical biofilm studies

 

Session code: 9c

 

ECCMID (https://www.eccmid.org/ (https://www.eccmid.org/) ) is the world's
premier Clinical Microbiology & Infectious Diseases event, bringing
together experts from many fields to present their latest findings, and
developments and share their expertise.

 

XF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially
being developed for the prevention of post-surgical staphylococcal infections,
such as methicillin-resistant Staphylococcus aureus (MRSA), which cause
significant complications and increased healthcare costs in the hospital
setting. XF-73 has been awarded both Qualified Infectious Disease Product
(QIDP) and Fast Track status by the US FDA.

 

If you would like to meet with Destiny Pharma, please email us at
conferences@destinypharma.com (mailto:conferences@destinypharma.com)

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Optimum Strategic Communications

Mary Clark / Manel Mateus /Vici Rabbetts

+44 (0) 208 078 4357

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SporCov, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

For further information on the company, please visit
https://www.destinypharma.com

About ECCMID

ECCMID (https://www.eccmid.org/ (https://www.eccmid.org/) ) is Europe's
premier Clinical Microbiology & Infectious Diseases event, bringing
together experts from many fields to present their latest findings, and
developments and share their expertise. The scientific programme is built by
the ECCMID Programme Committee, and independent group of experts representing
all disciplines related to clinical microbiology and infectious diseases.

 

About XF-73

XF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially
being developed for the prevention of post-surgical staphylococcal infections,
such as methicillin-resistant Staphylococcus aureus (MRSA), which cause
significant complications and increased healthcare costs in the hospital
setting. XF-73 has been awarded both Qualified Infectious Disease Product
(QIDP) and Fast Track status by the US FDA.

 

Forward looking statements

Certain information contained in this announcement, including any information
as to the Group's strategy, plans or future financial or operating
performance, constitutes "forward-looking statements". These forward-looking
statements may be identified by the use of forward-looking terminology,
including the terms "believes", "estimates", "anticipates", "projects",
"expects", "intends", "aims", "plans", "predicts", "may", "will", "seeks"
"could" "targets" "assumes" "positioned" or "should" or, in each case, their
negative or other variations or comparable terminology, or by discussions of
strategy, plans, objectives, goals, future events or intentions. These
forward-looking statements include all matters that are not historical facts.
They appear in a number of places throughout this announcement and include
statements regarding the intentions, beliefs or current expectations of the
Directors concerning, among other things, the Group's results of operations,
financial condition, prospects, growth, strategies and the industries in which
the Group operates. The directors of the company believe that the expectations
reflected in these statements are reasonable but may be affected by a number
of variables which could cause actual results or trends to differ materially.
Each forward-looking statement speaks only as of the date of the particular
statement. By their nature, forward-looking statements involve risks and
uncertainties because they relate to events and depend on circumstances that
may or may not occur in the future or are beyond the Group's control. Forward
looking statements are not guarantees of future performance. Even if the
Group's actual results of operations, financial condition and the development
of the industries in which the Group operates are consistent with the
forward-looking statements contained in this document, those results or
developments may not be indicative of results or developments in subsequent
periods.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKKBQABKDKNN